Radio and PodcastLive Radio & Podcasts

Search Radio and Podcast

Podcasts›Breaking Biotech›104 - Biotech Bear Market Offers SIGNIFICANT Opportunity in Oncology - CRIS! Longeveron Rises on ODD

Science & Medicine

104 - Biotech Bear Market Offers SIGNIFICANT Opportunity in Oncology - CRIS! Longeveron Rises on ODD

Breaking Biotech by Matthew Lepoire

Dec 12, 202100:48:17Science & Medicine

Curis is an oncology company trying to develop an inhibitor of IRAK-4. They have shown positive results in AML/MDS in spliceosome/FLT3 mutation patients as well as their non-target group. This will hopefully allow them t...

Related Episodes

Continue listening to more episodes from Breaking Biotech.

113 - Vaxxinity Takes on Neurodegenerative Diseases with Vaccines - Potential Short Opportunity?

May 8, 2022 - 00:45:36

Video Sponsor - In this episode, I go through a company called Vaxxinity, who are trying to develop vacci...

112 - Biotech Updates - $BTAI $TGTX $CRIS $CKPT $KPTI $SRRA

Apr 21, 2022 - 00:43:59

In this episode, I take a look at 6 different biotechs and talk about recent updates in each one. Here is...

111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John Bencich

Apr 1, 2022 - 00:28:19

Achieve Life Sciences is developing Cytisinicline for the treatment of smoking cessation. The drug has be...

110 - Kodiac Sciences FALLS on Negative Wet AMD Readout! Buying Opportunity or Falling Knife??

Mar 5, 2022 - 00:33:19

Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their...

109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results

Feb 22, 2022 - 00:33:42

Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBC...

108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLD

Feb 7, 2022 - 00:37:28

The NASH space has seen some setbacks in the last couple years, but a few players continue to make nice p...

107 - CymaBay Sets to Massively Improve Outcomes in PBC Patients Interview with CEO Sujal Shah

Jan 29, 2022 - 00:35:09

CymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholangitis (PBC). PBC...

106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!

Jan 9, 2022 - 00:42:53

CRISPR is an exciting space, with a number of companies finally sharing early clinical data in 2021. NTLA...